Science
Mitochondrial RNA leakage triggers immunosuppression Blocking PGE2 eliminated tumors in 9 of 10 mice

A mechanism by which chronic interferon exposure can actually promote tumor growth has been identified, offering clues to reversing resistance to immunotherapy.
According to a study published on the 28th in the international journal Science, researchers at the Salk Institute found for the first time that chronic type 2 interferon causes mitochondrial RNA to leak into the cytoplasm, creating an immunosuppressive environment.
Interferons normally help the immune system attack cancer cells. But the “dual nature” of interferons—acute exposure has anticancer effects, while chronic exposure induces immunosuppression and promotes tumor growth—has long been a puzzle.
The researchers treated melanoma cells with acute or chronic interferon exposure. Acute exposure caused no notable changes in the mitochondria, but chronic exposure produced measurable changes in energy function.
When melanoma cells treated with chronic type 2 interferon were transplanted into mice, tumor growth was not inhibited; instead, it was promoted.
Analysis of the mechanism showed that chronic type 2 interferon caused mitochondrial RNA to escape into the cytoplasm. The cells recognized it as an abnormal signal and began producing type 1 interferon.
Type 1 and type 2 interferons then jointly increased expression of the enzyme COX-2 and boosted synthesis of the immunosuppressive substance prostaglandin E2 (PGE2). PGE2 suppressed the anticancer immune response, allowing tumors to grow.
The researchers said that blocking PGE2 synthesis in mouse melanoma cells enabled the immune system to attack cancer cells again. In particular, in a model resistant to anti-PD-1 treatment, tumors completely disappeared in 9 of 10 mice after PGE2 was blocked, with no recurrence.
The researchers said, “This discovery brings the signaling function of mitochondria into tumor immunology research” and “also explains why interferons have opposite effects over time.”
However, these results came from cell and mouse models, and clinical application remains a long way off. The researchers proposed early inhibition of type 1 interferon signaling, blocking the release of mitochondrial RNA, and combining COX-2 inhibitors with immune checkpoint inhibitors as promising intervention strategies.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Blocking Disease Proteins With ‘Molecular Gates’ … Gate Bioscience Prepares to Enter the Clinic

Rezolute Meets Phase 3 Goal in Tumor Hyperinsulinism, Shares Rise Ahead of FDA Meeting

Regeneron’s POTS drug succeeds in Phase 2; Phase 3 to begin in first half of next year

Egene Receives Approval to Amend Phase 2/3 Trial of Quadrivalent Meningococcal Vaccine

GC Biopharma Develops Korea’s First Generative AI Drug Safety Monitoring Software, Focused on Preventing Missed Cases

Daewoong Pharmaceutical Wins Phase 1 Approval for Drug to Regenerate Intestinal Mucosa: “Beyond Immunosuppression”